IRadimed Corporation reported record fourth‑quarter 2025 results, with revenue of $22.7 million and GAAP net income of $6.4 million, up 17 % and 25 % respectively from the same quarter a year earlier. Non‑GAAP net income reached $7.0 million and diluted earnings per share of $0.54, beating consensus estimates of $0.49 and a revenue estimate of $21.60 million. The company’s first 3870 MRI‑compatible infusion pumps were shipped during the quarter, marking a key milestone in its product roadmap and contributing to the 20 % year‑over‑year growth in the MRI‑compatible IV infusion pump segment.
The 3870 pump launch has accelerated demand for IRadimed’s core product lines. The MRI‑compatible IV infusion pump system grew 20 % YoY in Q4 2025, while the patient vital‑signs monitoring system grew 7.5 %. These gains offset modest headwinds in legacy product channels and demonstrate the company’s ability to convert its unique non‑magnetic technology into higher‑margin revenue. Gross profit margins remained robust at 77 % for the full year and 75 % for the quarter, reflecting pricing power and efficient scale as the 3870 platform begins to capture market share.
Management raised full‑year 2026 revenue guidance to $91.0 million–$96.0 million and non‑GAAP diluted EPS to $2.06–$2.21, up from the prior 2025 guidance of $78.0 million–$82.0 million and $1.71–$1.81. The upward revision signals confidence that the 3870 pump will generate significant incremental revenue in the second half of 2026 and that the company’s operating leverage will improve as production ramps up. The guidance also reflects expectations of continued strong demand for MRI‑compatible devices and a growing installed base of older pump systems that will be replaced.
CEO Roger Susi highlighted the company’s momentum, noting that the 3870 launch “has been a key milestone” and that the firm is “well positioned to capture a growing market.” He also announced an increase in the quarterly cash dividend to $0.20 per share from $0.17, underscoring confidence in cash‑flow generation. Susi cautioned that the transition from the 3860 to the 3870 platform will require careful inventory management and that international regulatory approvals—CE Mark by end‑2026 and Japan by summer 2027—will be critical to sustaining growth.
The company acknowledges potential headwinds, including inventory challenges during the 3870 rollout and the time required to secure regulatory approvals outside the United States. Nevertheless, the strong earnings beat, robust margins, and raised guidance suggest that IRadimed’s strategic focus on MRI‑compatible technology is delivering tangible results and positioning the firm for continued expansion in a niche market with limited competition.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.